RIGL (Rigel Pharmaceuticals) Cyclically Adjusted FCF per Share: $-2.42 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RIGL Rigel Pharmaceuticals Inc RIGL
75 GF Score
Price $41.70
GF Value $26.78
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Cyclically Adjusted FCF per Share?

Rigel Pharmaceuticals RIGL +3.71% 75 Cyclically Adjusted FCF per Share is $-2.42 as of Jun. 2026. GuruFocus rates RIGL with a GF Score™ of 75/100 and a GF Value™ of $26.78 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Rigel Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was $1.566. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-2.42 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 19.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 16.20% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 13.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Rigel Pharmaceuticals was 28.30% per year. The lowest was 1.40% per year. And the median was 13.55% per year.

As of today (2026-08-10), Rigel Pharmaceuticals's current stock price is $41.70. Rigel Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $-2.42. Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


Rigel Pharmaceuticals  (NAS:RIGL) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Rigel Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Rigel Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.55 -5.88 -4.89 -3.79 -3.13

Rigel Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.71 -3.46 -3.13 -2.82 -2.42

RIGL vs SGP, OCS, GYRE: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


RIGL
75GF Score
Rigel Pharmaceuticals Inc RIGL
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rigel Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rigel Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.566/333.9520*333.9520
=1.566

Current CPI (Jun. 2026) = 333.9520.

Rigel Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -2.391 241.428 -3.307
201612 -1.259 241.432 -1.741
201703 -1.831 243.801 -2.508
201706 -1.591 244.955 -2.169
201709 -1.417 246.819 -1.917
201712 -1.369 246.524 -1.855
201803 -1.604 249.554 -2.146
201806 -1.713 251.989 -2.270
201809 -1.216 252.439 -1.609
201812 0.694 251.233 0.923
201903 -0.057 254.202 -0.075
201906 -1.003 256.143 -1.308
201909 -0.895 256.759 -1.164
201912 -0.612 256.974 -0.795
202003 -0.219 258.115 -0.283
202006 -0.830 257.797 -1.075
202009 -1.165 260.280 -1.495
202012 -0.951 260.474 -1.219
202103 -1.137 264.877 -1.434
202106 3.220 271.696 3.958
202109 -0.612 274.310 -0.745
202112 -1.114 278.802 -1.334
202203 -1.506 287.504 -1.749
202206 -0.748 296.311 -0.843
202209 -0.780 296.808 -0.878
202212 -1.331 296.797 -1.498
202303 -1.099 301.836 -1.216
202306 0.342 305.109 0.374
202309 -0.078 307.789 -0.085
202312 -0.358 306.746 -0.390
202403 -0.294 312.332 -0.314
202406 0.005 314.175 0.005
202409 1.228 315.301 1.301
202412 0.806 315.605 0.853
202503 -0.049 319.799 -0.051
202506 1.681 322.561 1.740
202509 1.254 324.800 1.289
202512 1.087 324.054 1.120
202603 0.138 330.213 0.140
202606 1.566 333.952 1.566

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-2.42 mean?
Rigel Pharmaceuticals (RIGL) has a Cyclically Adjusted FCF per Share of $-2.42 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Rigel Pharmaceuticals and its competitors.
Is Rigel Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Rigel Pharmaceuticals' current Cyclically Adjusted FCF per Share is $-2.42. Overall, Rigel Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Cyclically Adjusted FCF per Share compare to SGP and OCS?
Rigel Pharmaceuticals' Cyclically Adjusted FCF per Share of $-2.42 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current Cyclically Adjusted FCF per Share is $-2.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rigel Pharmaceuticals (RIGL) is currently considered Significantly Overvalued. The stock's GF Value™ is $26.78, compared to a current price of $41.70 — trading 55.7% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-2.42. Rigel Pharmaceuticals' overall GF Score™ is 75/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Rigel Pharmaceuticals (RIGL), the current Cyclically Adjusted FCF per Share is $-2.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (RIGL) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of $41.70 is trading 55.7% above its estimated GF Value™ of $26.78. GuruFocus considers Rigel Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for RIGL:

  • Cyclically Adjusted FCF per Share: $-2.42
  • GF Value™: $26.78 vs. price of $41.70 (55.7% above fair value)
  • GF Score™: 75/100 with 8 warning signs

No single metric tells the full story. See the RIGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rigel Pharmaceuticals Business Description

Other Exchanges RI2:Germany
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
75GF Score

Get the complete analysis for RIGL

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.70
Price
$26.78
GF Value